 Miriam Post
Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stillbirth | 2 | 2024 | 59 | 1.730 |
Why?
| | Placenta | 10 | 2024 | 706 | 1.670 |
Why?
| | Ovarian Neoplasms | 15 | 2024 | 474 | 1.560 |
Why?
| | Uterine Neoplasms | 6 | 2019 | 101 | 1.220 |
Why?
| | Carcinosarcoma | 5 | 2018 | 17 | 1.160 |
Why?
| | Cystadenocarcinoma, Serous | 7 | 2024 | 66 | 1.120 |
Why?
| | Fetal Death | 1 | 2023 | 55 | 0.870 |
Why?
| | Clinical Competence | 3 | 2022 | 1020 | 0.840 |
Why?
| | Pathologists | 3 | 2017 | 15 | 0.780 |
Why?
| | Endometrial Neoplasms | 6 | 2023 | 163 | 0.760 |
Why?
| | Education, Medical, Continuing | 1 | 2022 | 123 | 0.730 |
Why?
| | Microfilament Proteins | 1 | 2017 | 130 | 0.540 |
Why?
| | Hemangioma, Capillary | 1 | 2015 | 13 | 0.480 |
Why?
| | Fetal Growth Retardation | 3 | 2024 | 542 | 0.470 |
Why?
| | Autopsy | 2 | 2024 | 89 | 0.440 |
Why?
| | Lymph Nodes | 4 | 2018 | 458 | 0.430 |
Why?
| | Carrier Proteins | 1 | 2017 | 728 | 0.430 |
Why?
| | Pre-Eclampsia | 2 | 2021 | 183 | 0.420 |
Why?
| | Fetus | 3 | 2024 | 764 | 0.420 |
Why?
| | Tumor Microenvironment | 3 | 2024 | 588 | 0.400 |
Why?
| | Female | 54 | 2024 | 68162 | 0.380 |
Why?
| | Pathology | 3 | 2017 | 15 | 0.380 |
Why?
| | Immunohistochemistry | 8 | 2023 | 1694 | 0.380 |
Why?
| | Pregnancy | 11 | 2024 | 6247 | 0.370 |
Why?
| | Biomarkers, Tumor | 10 | 2024 | 1170 | 0.360 |
Why?
| | Prognosis | 11 | 2024 | 3787 | 0.340 |
Why?
| | Humans | 61 | 2024 | 128896 | 0.330 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2022 | 72 | 0.330 |
Why?
| | Osteoblastoma | 1 | 2008 | 2 | 0.320 |
Why?
| | Prolactinoma | 1 | 2008 | 12 | 0.320 |
Why?
| | Skull Base | 1 | 2008 | 42 | 0.310 |
Why?
| | Skull Base Neoplasms | 1 | 2008 | 24 | 0.310 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2008 | 55 | 0.300 |
Why?
| | Cytomegalovirus | 1 | 2009 | 156 | 0.290 |
Why?
| | Diagnosis, Differential | 6 | 2024 | 1435 | 0.290 |
Why?
| | Fetal Diseases | 1 | 2009 | 148 | 0.290 |
Why?
| | Peritoneal Neoplasms | 3 | 2014 | 83 | 0.280 |
Why?
| | Lymphatic Vessels | 2 | 2018 | 59 | 0.280 |
Why?
| | Uterus | 3 | 2022 | 204 | 0.280 |
Why?
| | Professionalism | 2 | 2017 | 17 | 0.280 |
Why?
| | Interleukin-6 | 3 | 2024 | 715 | 0.270 |
Why?
| | Cytomegalovirus Infections | 1 | 2009 | 190 | 0.270 |
Why?
| | Pituitary Neoplasms | 1 | 2008 | 184 | 0.270 |
Why?
| | Gestational Age | 4 | 2024 | 857 | 0.270 |
Why?
| | Receptors, Estrogen | 5 | 2017 | 423 | 0.260 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2009 | 334 | 0.240 |
Why?
| | Infant, Newborn | 4 | 2024 | 5704 | 0.230 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 952 | 0.230 |
Why?
| | Education, Medical, Graduate | 4 | 2017 | 436 | 0.220 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2021 | 233 | 0.220 |
Why?
| | Tryptophan Oxygenase | 1 | 2024 | 31 | 0.220 |
Why?
| | Chorionic Villi | 1 | 2024 | 22 | 0.220 |
Why?
| | Breast Neoplasms | 4 | 2024 | 2112 | 0.220 |
Why?
| | Middle Aged | 22 | 2024 | 30977 | 0.220 |
Why?
| | Umbilical Arteries | 1 | 2024 | 49 | 0.220 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2024 | 1312 | 0.220 |
Why?
| | Neoplasm Invasiveness | 6 | 2018 | 479 | 0.220 |
Why?
| | Cell Line, Tumor | 11 | 2024 | 3100 | 0.210 |
Why?
| | Hypertension, Pulmonary | 1 | 2015 | 1876 | 0.210 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 67 | 0.210 |
Why?
| | Internship and Residency | 3 | 2017 | 1052 | 0.210 |
Why?
| | Choriocarcinoma | 1 | 2022 | 8 | 0.210 |
Why?
| | Endodermal Sinus Tumor | 1 | 2022 | 8 | 0.210 |
Why?
| | Neoplasm Staging | 5 | 2019 | 1285 | 0.210 |
Why?
| | Dendritic Cell Sarcoma, Follicular | 1 | 2022 | 2 | 0.200 |
Why?
| | Fallopian Tubes | 1 | 2022 | 31 | 0.200 |
Why?
| | Carcinoma, Endometrioid | 2 | 2022 | 46 | 0.200 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 147 | 0.200 |
Why?
| | Lung Neoplasms | 2 | 2015 | 2353 | 0.200 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2023 | 319 | 0.200 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 88 | 0.200 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2021 | 626 | 0.200 |
Why?
| | Specialty Boards | 1 | 2022 | 33 | 0.200 |
Why?
| | Hysterectomy | 3 | 2022 | 118 | 0.190 |
Why?
| | Antigens, CD | 2 | 2015 | 479 | 0.190 |
Why?
| | Premature Birth | 2 | 2024 | 313 | 0.190 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 66 | 0.190 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2021 | 10 | 0.190 |
Why?
| | Certification | 1 | 2022 | 93 | 0.190 |
Why?
| | Granulosa Cells | 1 | 2021 | 32 | 0.190 |
Why?
| | beta Catenin | 2 | 2023 | 220 | 0.190 |
Why?
| | Ovarian Follicle | 1 | 2021 | 63 | 0.180 |
Why?
| | Ovary | 1 | 2022 | 212 | 0.180 |
Why?
| | Artificial Intelligence | 1 | 2024 | 233 | 0.180 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2023 | 732 | 0.180 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2022 | 225 | 0.180 |
Why?
| | Decidua | 2 | 2012 | 23 | 0.180 |
Why?
| | Adult | 22 | 2024 | 35361 | 0.170 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 484 | 0.170 |
Why?
| | Neovascularization, Physiologic | 1 | 2021 | 179 | 0.170 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 203 | 0.160 |
Why?
| | Phthalazines | 1 | 2019 | 38 | 0.160 |
Why?
| | Leiomyosarcoma | 1 | 2019 | 27 | 0.160 |
Why?
| | Endometrium | 2 | 2022 | 61 | 0.160 |
Why?
| | Histocompatibility Antigens | 1 | 2019 | 107 | 0.160 |
Why?
| | Estrogens | 2 | 2012 | 348 | 0.160 |
Why?
| | Leiomyoma | 1 | 2019 | 73 | 0.150 |
Why?
| | Gene Expression Profiling | 4 | 2019 | 1694 | 0.150 |
Why?
| | Antineoplastic Agents | 2 | 2023 | 2038 | 0.150 |
Why?
| | Up-Regulation | 1 | 2021 | 848 | 0.150 |
Why?
| | Diverticulum | 1 | 2018 | 11 | 0.150 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2018 | 14 | 0.150 |
Why?
| | Uterine Diseases | 1 | 2018 | 15 | 0.150 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2019 | 126 | 0.150 |
Why?
| | Adenocarcinoma | 2 | 2015 | 895 | 0.150 |
Why?
| | Piperazines | 1 | 2019 | 326 | 0.140 |
Why?
| | Fetal Blood | 2 | 2021 | 315 | 0.140 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2017 | 61 | 0.140 |
Why?
| | Extracellular Matrix | 1 | 2021 | 493 | 0.140 |
Why?
| | B7-H1 Antigen | 3 | 2024 | 174 | 0.140 |
Why?
| | Blood Vessels | 1 | 2018 | 184 | 0.130 |
Why?
| | Retinopathy of Prematurity | 1 | 2018 | 128 | 0.130 |
Why?
| | Cisplatin | 2 | 2015 | 292 | 0.130 |
Why?
| | Neoplasm Grading | 3 | 2024 | 277 | 0.130 |
Why?
| | Cell Proliferation | 5 | 2015 | 2337 | 0.130 |
Why?
| | Employment | 1 | 2017 | 161 | 0.130 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 35 | 0.130 |
Why?
| | Job Satisfaction | 1 | 2017 | 197 | 0.130 |
Why?
| | Endothelial Cells | 1 | 2021 | 734 | 0.130 |
Why?
| | Pelvic Neoplasms | 1 | 2015 | 19 | 0.120 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 35 | 0.120 |
Why?
| | Aged | 13 | 2024 | 22035 | 0.120 |
Why?
| | Receptors, Progesterone | 3 | 2015 | 342 | 0.120 |
Why?
| | Keratin-5 | 1 | 2015 | 49 | 0.120 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2015 | 33 | 0.120 |
Why?
| | Incidental Findings | 1 | 2015 | 80 | 0.120 |
Why?
| | Mutation | 2 | 2023 | 3671 | 0.120 |
Why?
| | Skin Neoplasms | 2 | 2012 | 828 | 0.120 |
Why?
| | Tuberous Sclerosis | 1 | 2015 | 49 | 0.120 |
Why?
| | Oxidative Stress | 1 | 2021 | 1220 | 0.120 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 157 | 0.120 |
Why?
| | Mesothelioma, Cystic | 1 | 2014 | 1 | 0.120 |
Why?
| | Capillaries | 1 | 2015 | 98 | 0.120 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2014 | 35 | 0.110 |
Why?
| | Chest Pain | 1 | 2015 | 89 | 0.110 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2024 | 508 | 0.110 |
Why?
| | Chorioamnionitis | 1 | 2014 | 38 | 0.110 |
Why?
| | Carcinoma | 1 | 2016 | 214 | 0.110 |
Why?
| | Educational Measurement | 1 | 2016 | 259 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2019 | 797 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1204 | 0.110 |
Why?
| | Lymphatic Metastasis | 4 | 2018 | 312 | 0.110 |
Why?
| | Cough | 1 | 2015 | 118 | 0.110 |
Why?
| | Sarcoma | 1 | 2016 | 173 | 0.110 |
Why?
| | Accreditation | 1 | 2014 | 81 | 0.110 |
Why?
| | Fertility Preservation | 1 | 2014 | 54 | 0.110 |
Why?
| | Glycoproteins | 1 | 2015 | 340 | 0.110 |
Why?
| | Adenomyosis | 1 | 2013 | 1 | 0.110 |
Why?
| | Survival Rate | 4 | 2018 | 1884 | 0.110 |
Why?
| | Interleukin-8 | 1 | 2014 | 261 | 0.110 |
Why?
| | Robotics | 1 | 2014 | 88 | 0.100 |
Why?
| | Dyspnea | 1 | 2015 | 236 | 0.100 |
Why?
| | Gestational Trophoblastic Disease | 1 | 2012 | 5 | 0.100 |
Why?
| | Luteinizing Hormone | 1 | 2013 | 177 | 0.100 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 25 | 0.100 |
Why?
| | Infertility | 1 | 2013 | 50 | 0.100 |
Why?
| | Fatigue | 1 | 2015 | 319 | 0.100 |
Why?
| | Neural Stem Cells | 1 | 2014 | 132 | 0.100 |
Why?
| | Menstrual Cycle | 1 | 2013 | 124 | 0.100 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2012 | 60 | 0.100 |
Why?
| | Lectins | 1 | 2012 | 46 | 0.100 |
Why?
| | Retrospective Studies | 9 | 2024 | 14546 | 0.100 |
Why?
| | Carcinoma, Lobular | 1 | 2012 | 46 | 0.100 |
Why?
| | Interleukin-1beta | 1 | 2014 | 376 | 0.100 |
Why?
| | Antibodies, Neoplasm | 1 | 2012 | 35 | 0.100 |
Why?
| | Cicatrix | 1 | 2012 | 56 | 0.100 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2011 | 15 | 0.100 |
Why?
| | Endometriosis | 1 | 2012 | 49 | 0.100 |
Why?
| | Apoptosis | 4 | 2015 | 2481 | 0.090 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 376 | 0.090 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 33 | 0.090 |
Why?
| | Lymph Node Excision | 3 | 2018 | 166 | 0.090 |
Why?
| | DNA Polymerase II | 2 | 2023 | 38 | 0.090 |
Why?
| | Paclitaxel | 1 | 2012 | 214 | 0.090 |
Why?
| | Nervous System Diseases | 1 | 2014 | 260 | 0.090 |
Why?
| | Leptin | 1 | 2012 | 217 | 0.090 |
Why?
| | Bridged-Ring Compounds | 1 | 2011 | 13 | 0.090 |
Why?
| | Diagnostic Errors | 1 | 2012 | 163 | 0.090 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2011 | 24 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2012 | 198 | 0.090 |
Why?
| | Trophoblastic Neoplasms | 1 | 2010 | 2 | 0.090 |
Why?
| | Carcinoma, Large Cell | 1 | 2010 | 16 | 0.090 |
Why?
| | United States | 4 | 2022 | 13975 | 0.090 |
Why?
| | Neoplasms, Squamous Cell | 1 | 2010 | 4 | 0.090 |
Why?
| | Taxoids | 1 | 2011 | 98 | 0.090 |
Why?
| | Cesarean Section | 1 | 2012 | 180 | 0.090 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2010 | 33 | 0.090 |
Why?
| | Biological Evolution | 1 | 2014 | 426 | 0.090 |
Why?
| | Skin Diseases | 1 | 2012 | 143 | 0.090 |
Why?
| | Graft vs Host Disease | 1 | 2012 | 238 | 0.090 |
Why?
| | Peptides | 1 | 2015 | 902 | 0.090 |
Why?
| | Inflammation | 2 | 2018 | 2694 | 0.080 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1090 | 0.080 |
Why?
| | Mice | 8 | 2024 | 16543 | 0.080 |
Why?
| | Genital Neoplasms, Female | 1 | 2010 | 80 | 0.080 |
Why?
| | Biopsy | 3 | 2022 | 1093 | 0.080 |
Why?
| | Amniocentesis | 1 | 2009 | 23 | 0.080 |
Why?
| | Africa, Eastern | 1 | 2009 | 11 | 0.080 |
Why?
| | Fever of Unknown Origin | 1 | 2009 | 10 | 0.080 |
Why?
| | Infarction | 1 | 2008 | 12 | 0.080 |
Why?
| | Prolactin | 1 | 2008 | 99 | 0.080 |
Why?
| | Blood Chemical Analysis | 1 | 2008 | 94 | 0.070 |
Why?
| | Homeodomain Proteins | 1 | 2012 | 480 | 0.070 |
Why?
| | Viremia | 1 | 2009 | 133 | 0.070 |
Why?
| | Travel | 1 | 2009 | 123 | 0.070 |
Why?
| | Models, Statistical | 1 | 2011 | 626 | 0.070 |
Why?
| | Headache | 1 | 2008 | 138 | 0.070 |
Why?
| | Immunoglobulin M | 1 | 2009 | 268 | 0.070 |
Why?
| | Neoplasm Proteins | 1 | 2010 | 428 | 0.070 |
Why?
| | Animals | 10 | 2024 | 34628 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2012 | 576 | 0.070 |
Why?
| | Ultrasonography, Prenatal | 1 | 2009 | 266 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2017 | 5355 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2021 | 3334 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 211 | 0.070 |
Why?
| | Macrophages | 2 | 2024 | 1452 | 0.070 |
Why?
| | MicroRNAs | 1 | 2012 | 668 | 0.060 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2018 | 380 | 0.060 |
Why?
| | Survival Analysis | 2 | 2021 | 1282 | 0.060 |
Why?
| | Mice, Nude | 3 | 2012 | 680 | 0.060 |
Why?
| | Disease Progression | 3 | 2019 | 2603 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2024 | 7050 | 0.060 |
Why?
| | Cohort Studies | 3 | 2024 | 5394 | 0.060 |
Why?
| | Immunoglobulin G | 1 | 2009 | 834 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2018 | 4917 | 0.060 |
Why?
| | BRCA2 Protein | 1 | 2024 | 52 | 0.060 |
Why?
| | Prospective Studies | 3 | 2023 | 7060 | 0.060 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2024 | 46 | 0.060 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 45 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2024 | 310 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2024 | 118 | 0.050 |
Why?
| | Kynurenine | 1 | 2024 | 102 | 0.050 |
Why?
| | Activating Transcription Factor 6 | 1 | 2023 | 16 | 0.050 |
Why?
| | Tryptophan | 1 | 2024 | 166 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 85 | 0.050 |
Why?
| | Brain | 1 | 2014 | 2592 | 0.050 |
Why?
| | Ultrasonography | 2 | 2018 | 727 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1570 | 0.050 |
Why?
| | Lung | 1 | 2015 | 3925 | 0.050 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 28 | 0.050 |
Why?
| | Mice, SCID | 2 | 2012 | 340 | 0.050 |
Why?
| | Maternal Age | 1 | 2021 | 121 | 0.050 |
Why?
| | Cervix Uteri | 1 | 2021 | 50 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2022 | 200 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2013 | 3348 | 0.050 |
Why?
| | Open Reading Frames | 1 | 2021 | 123 | 0.050 |
Why?
| | Ligands | 1 | 2022 | 614 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 79 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2024 | 827 | 0.040 |
Why?
| | Young Adult | 4 | 2021 | 12286 | 0.040 |
Why?
| | Estradiol | 2 | 2013 | 494 | 0.040 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2019 | 20 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 800 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2019 | 67 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 35 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 409 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 81 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 141 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2008 | 2530 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2021 | 448 | 0.040 |
Why?
| | Fetal Development | 1 | 2021 | 283 | 0.040 |
Why?
| | Ovarian Cysts | 1 | 2018 | 7 | 0.040 |
Why?
| | Pregnancy, Tubal | 1 | 2018 | 5 | 0.040 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 18 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 1967 | 0.040 |
Why?
| | Salpingectomy | 1 | 2018 | 13 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 182 | 0.040 |
Why?
| | Pelvic Pain | 1 | 2018 | 34 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 148 | 0.040 |
Why?
| | Frozen Sections | 1 | 2018 | 26 | 0.040 |
Why?
| | Abortion, Spontaneous | 1 | 2018 | 97 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 422 | 0.040 |
Why?
| | Phosphorylation | 1 | 2021 | 1685 | 0.030 |
Why?
| | Risk Factors | 3 | 2018 | 9792 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 932 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 659 | 0.030 |
Why?
| | Ifosfamide | 1 | 2016 | 33 | 0.030 |
Why?
| | Abortion, Induced | 1 | 2018 | 95 | 0.030 |
Why?
| | Faculty | 1 | 2017 | 132 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2015 | 19 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 382 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 55 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2759 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2019 | 576 | 0.030 |
Why?
| | Risk | 1 | 2018 | 866 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 871 | 0.030 |
Why?
| | Cell Count | 1 | 2015 | 316 | 0.030 |
Why?
| | Receptors, Androgen | 1 | 2015 | 141 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2014 | 30 | 0.030 |
Why?
| | Histones | 1 | 2019 | 584 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1840 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1905 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 657 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2017 | 271 | 0.030 |
Why?
| | Follicular Phase | 1 | 2013 | 40 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2012 | 2700 | 0.030 |
Why?
| | Laparoscopy | 1 | 2018 | 452 | 0.030 |
Why?
| | Hysteroscopy | 1 | 2013 | 10 | 0.030 |
Why?
| | Luteal Phase | 1 | 2013 | 44 | 0.030 |
Why?
| | Male | 4 | 2017 | 63146 | 0.030 |
Why?
| | Primates | 1 | 2014 | 120 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 446 | 0.030 |
Why?
| | Cryopreservation | 1 | 2014 | 99 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1545 | 0.030 |
Why?
| | Oocytes | 1 | 2014 | 178 | 0.030 |
Why?
| | Vaginal Neoplasms | 1 | 2012 | 12 | 0.030 |
Why?
| | Karyotyping | 1 | 2012 | 107 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1100 | 0.030 |
Why?
| | Anoikis | 1 | 2012 | 32 | 0.030 |
Why?
| | Cell Survival | 1 | 2015 | 1082 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2012 | 128 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 822 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 723 | 0.020 |
Why?
| | Tamoxifen | 1 | 2012 | 198 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2014 | 832 | 0.020 |
Why?
| | Perioperative Period | 1 | 2011 | 49 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2012 | 185 | 0.020 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2011 | 54 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2012 | 190 | 0.020 |
Why?
| | Tubulin | 1 | 2012 | 131 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 284 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2012 | 452 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 579 | 0.020 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2010 | 26 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2010 | 67 | 0.020 |
Why?
| | Cell Cycle Checkpoints | 1 | 2011 | 95 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2010 | 210 | 0.020 |
Why?
| | Transfection | 1 | 2012 | 904 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 3874 | 0.020 |
Why?
| | Organ Specificity | 1 | 2010 | 296 | 0.020 |
Why?
| | Mitosis | 1 | 2011 | 177 | 0.020 |
Why?
| | Adolescent | 1 | 2008 | 20197 | 0.020 |
Why?
| | HeLa Cells | 1 | 2011 | 602 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 987 | 0.020 |
Why?
| | Microtubules | 1 | 2011 | 252 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2010 | 772 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 957 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1188 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1045 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5032 | 0.020 |
Why?
| | Chronic Disease | 1 | 2012 | 1715 | 0.020 |
Why?
| | Cytokines | 1 | 2014 | 1995 | 0.020 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2012 | 593 | 0.020 |
Why?
| | Infant | 1 | 2018 | 8994 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2767 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 10239 | 0.010 |
Why?
| | Signal Transduction | 1 | 2011 | 4857 | 0.010 |
Why?
|
|
Post's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|